Avenue Therapeutics, Inc. (ATXI)
After hours:
| Previous close | 4.5100 |
| Open | 4.4700 |
| Bid | 3.9700 x 100 |
| Ask | 4.3900 x 100 |
| Day's range | 4.0430 - 5.9700 |
| 52-week range | 4.0430 - 93.7500 |
| Volume | |
| Avg. volume | 37,762 |
| Market cap | 2.501M |
| Beta (5Y monthly) | -0.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -73.5000 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.25 |
GlobeNewswireAvenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock. The exercised warrants are comprised of warrants to purchase sh
- GlobeNewswire
Avenue Therapeutics Announces Reverse Stock Split
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on Apr
- GlobeNewswire
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi
